Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Convertible Debt (2016 - 2021)

Rocket Pharmaceuticals (RCKT) has disclosed Convertible Debt for 6 consecutive years, with $35.5 million as the latest value for Q1 2021.

  • Quarterly Convertible Debt fell 22.38% to $35.5 million in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $35.5 million through Mar 2021, down 22.38% year-over-year, with the annual reading at $35.1 million for FY2020, 22.16% down from the prior year.
  • Convertible Debt hit $35.5 million in Q1 2021 for Rocket Pharmaceuticals, up from $35.1 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $49.4 million in Q3 2017 to a low of $35.1 million in Q4 2020.
  • Historically, Convertible Debt has averaged $43.0 million across 5 years, with a median of $42.7 million in 2019.
  • Biggest five-year swings in Convertible Debt: grew 8.69% in 2019 and later fell 22.38% in 2021.
  • Year by year, Convertible Debt stood at $49.4 million in 2017, then fell by 16.08% to $41.4 million in 2018, then grew by 8.69% to $45.0 million in 2019, then fell by 22.16% to $35.1 million in 2020, then increased by 1.36% to $35.5 million in 2021.
  • Business Quant data shows Convertible Debt for RCKT at $35.5 million in Q1 2021, $35.1 million in Q4 2020, and $42.1 million in Q3 2020.